

1 **Research article: Single Channel Electrocardiography Optimizes the Diagnostic**  
2 **Accuracy of Bicycle Ergometry!**

3 Running title: Recent advances in IHD diagnosis

4  
5 **Authors' list: Basheer Abdullah Marzoog<sup>1,\*</sup>, Magomed Abdullaev<sup>1</sup>, Alexander**  
6 **Suvorov<sup>1</sup>, Peter Chomakhidze<sup>1</sup>, Daria Gognieva<sup>1</sup>, Nina Vladimirovna Gagarina<sup>2</sup>,**  
7 **Natalia Mozzhukhina<sup>3</sup>, Sergey Vladimirovich Kostin<sup>4</sup>, Afina Aftandilovna**  
8 **Bestavashvili<sup>1</sup>, Ekaterina Fominykha<sup>2</sup>, Philipp Kopylov<sup>1</sup>**

9 <sup>1</sup> World-Class Research Center «Digital Biodesign and Personalized Healthcare», I.M.  
10 Sechenov First Moscow State Medical University (Sechenov University), 119991 Moscow,  
11 Russia; postal address: Russia, Moscow, 8-2 Trubetskaya street, 119991.

12 <sup>2</sup> University clinical Hospital number 1, Radiology department, I.M. Sechenov First Moscow  
13 State Medical University (Sechenov University), 119991 Moscow, Russia; postal address:  
14 Russia, Moscow, 8-2 Trubetskaya street, 119991.

15 <sup>3</sup> University clinical Hospital number 1, Health Management Clinic, I.M. Sechenov First  
16 Moscow State Medical University (Sechenov University), 119991 Moscow, Russia; postal  
17 address: Russia, Moscow, 8-2 Trubetskaya street, 119991.

18 <sup>4</sup> National Research Ogarev Mordovia State University. Russia. Republic of Mordovia.  
19 Saransk. Bolshevistskaya str. 68, Saransk. Mordovia Republic. 430005. email:  
20 drmosalah@mail.ru.

21 \*Corresponding author: Basheer Abdullah Marzoog, M.D., Ph.D. cardiology student at  
22 Sechenov First Moscow State Medical University at the World-Class Research Center  
23 "Digital biodesign and personalized healthcare". (marzug@mail.ru, +79969602820).  
24 Address: Russia, Moscow, 8-2 Trubetskaya street, 119991. Postal address: Russia, Moscow,  
25 8-2 Trubetskaya street, 119991. ORCID: 0000-0001-5507-2413, Scopus ID: 57486338800

26  
27 Competing interests: No competing interests regarding the publication.

28  
29  
30  
31  
32  
33  
34

35 **Abstract**

36 **Background:** Cardiovascular disease (CVD) such as ischemic heart disease impacts the  
37 people quality of life and has the highest mortality rate in the globe. This returns to the poor  
38 diagnostic and therapeutic strategies including the early prevention methods.

39 **Aims:** To assess the changes in the single channel electrocardiography (SCECG) in rest and  
40 on exercise test in patients with vs without ischemic heart disease confirmed by stress  
41 computed tomography myocardial perfusion (CTP) imaging.

42 **Objectives:** Ischemic heart disease patients frequently have preventable risk factors and  
43 causes that lead to the disease appearance. However, the lack of the proper diagnostic and  
44 prevention tools remains a global challenge in our era despite the current scientific advances.

45 **Material and methods:** A cohort, prospective, single center observational study included 38  
46 participants from Moscow. The participants aged  $\geq 40$  years and given a written consent to  
47 participate in the study. The participants subdivided into two groups according to the  
48 presence or absence of the myocardial perfusion defect on the CTP with vasodilatation stress-  
49 test. Both groups (group 1 with myocardial perfusion defect (n=19), group 2 without  
50 myocardial perfusion defect (n=19)) passed general primary consultation by cardiologist,  
51 anthropometric measurements, recording 3-minutes single channel electrocardiography  
52 (ECG) in rest before and just after exercise test, blood pressure and pulse rate using automatic  
53 tonometer, echocardiography, cardio-ankle vascular index, performing ergometry,  
54 immediately repeating the single channel ECG, then performing CTP. LASSO regression  
55 with nested cross-validation was used to find association between Cardio-Qvark parameters  
56 and the existence of the perfusion defect. Statistical processing was carried out using the R  
57 programming language v4.2 and Python v.3.10 [^R].

58 **Results:** The study results showed that the single channel ECG have significantly higher  
59 diagnostic accuracy in compare to bicycle ergometry. The specificity 63.2 % [95 %  
60 confidence interval (CI); 0.391 ; 0.833], sensitivity 73.7 % [95 % CI ; 0.533 ; 0.929], and  
61 accuracy of the diagnostic method using exhaled breath analysis, area under the curve (AUC)  
62 68.4 % [95 % CI ; 0.527 ; 0.817].

63 **Conclusion:** Single channel ECG (Cardio-Qvark) has the potential to improve the diagnostic  
64 accuracy of the bicycle ergometry.

65 **Other:** Further investigations required to uncover the hidden capabilities of Cardio-Qvark in  
66 the diagnosis of ischemic heart disease.

67 **Keywords:** IHD, Single channel electrocardiography, CTP, Prevention, Risk Factors, Stress  
68 Test, Machine Learning Model

69 **Introduction**

70 Ischemic heart disease remains the leading challenge in terms of mortality and morbidity  
71 despite the advances in the used methods for diagnosis and prevention. However, the early  
72 prevention in terms of evaluation of the ischemic heart disease in early period still  
73 underestimated. The current attention of the scientists paid to the prevention rather than  
74 diagnosis and treatment. In this manner, the scientific community developed several cost-  
75 effective methods to be confirmed for clinical use for early prevention of ischemic heart  
76 disease, including the use of the single channel electrocardiography and exhaled breath  
77 analysis in coronary heart disease prevention [1].

78 **Material and methods**

79 A prospective single center cohort study included 38 participants. According to the results of  
80 the CTP, the participants divided in to two groups. The first group participants without  
81 myocardial perfusion defect and the second group with myocardial perfusion defect on the  
82 CTP. The participants are randomly chosen. A written consent has been taken from the  
83 participants. The study registered on clinicaltrials.gov (NCT06181799), and the study  
84 approved by the ethical commitment of the Sechenov University, Russia, from “Ethics  
85 Committee Requirement № 19-23 from 26.10.2023”.

86 The study evaluated continuous and categorical variables. The continuous variables included;  
87 age, pulse at rest, systolic blood pressure (SBP) at rest, diastolic blood pressure (DBP) at rest,  
88 body weight, height, maximum heart rate (HR) on physical stress test, watt (WT) on physical  
89 stress test, metabolic equivalent (METs) on physical stress test, reached percent on physical  
90 stress test , ejection fraction (EF %) on echocardiography, estimated vessel age, right cardio-  
91 ankle vascular index (R-CAVI), left Cardio-ankle vascular index (L-CAVI), right ankle-  
92 brachial index (RABI), left ankle-brachial index (LABI), mean SBP brachial (SBPB)  $(=(\text{right SBPB} + \text{left SBPB})/2)$ , mean DBPB  $(=(\text{right DBPB} + \text{left DBPB})/2)$ , BP right brachial  
93 (BPRB)  $(=(\text{SBP} + \text{DBP})/2)$ , BP left brachial (BPLB)  $(=(\text{SBP} + \text{DBP})/2)$ , mean BPB  $(=(\text{BPRB} + \text{BPLB})/2)$ , BP right ankle (BPRA)  $(=(\text{SBP} + \text{DBP})/2)$ , BP left ankle (BPLA)  
94  $(=(\text{SBP} + \text{DBP})/2)$ , mean BPA  $(=(\text{BPRA} + \text{BPLA})/2)$ , mean ankle-brachial index (ABI), right  
95 brachial pulse (RTb), left brachial pulse (LTb), mean Tb  $(=(\text{LTb} + \text{RTb})/2)$ , right brachial-  
96 ankle pulse (Tba), left brachial-ankle pulse (Tba), mean Tba  $(=(\text{left Tba} + \text{right Tba})/2)$ ,  
97 length heart-ankle (Lha in cm), heart-ankle pulse wave velocity (haPWV; m/s),  $\beta$ -stiffness  
98 index from PWV, creatinine ( $\mu\text{mol/L}$ ) , and eGFR (2021 CKD-EPI Creatinine). The  
99 categorical variables included; gender, obesity stage, smoking, concomitant disease,  
100 atherosclerosis of the coronary artery, hemodynamically significant ( $>60\%$ ), myocardial  
101  
102

103 perfusion defect after stress ATP, myocardial perfusion defect before stress ATP,  
104 atherosclerosis in other arteries (Yes/No), brachiocephalic, hypertension (AH), stage AH,  
105 degree AH, risk of cardiovascular disease (CVD), stable coronary artery disease (SCAD),  
106 functional class (FC) by WT, FC by METs, reaction type to stress test(positive/negative), and  
107 reason of discontinuation of the stress test.

108 The study used the following ECG parameters:

- 109 • QTc duration (Bazett's formula);
- 110 • amplitude parameters (JA is the amplitude at point J in microV, TA is the amplitude of the  
111 T-wave in microV, PAn is the amplitude of the negative P-wave in microV);
- 112 • indices of asymmetry SBeta, Beta (ratio of the maximum modulus of the derivative value at  
113 the leading front of the T-wave to the maximum modulus of the value at the trailing front of  
114 the T-wave);
- 115 • spectral integrals of energy of R and T waves: QRS1energy (leading front of R—1st  
116 derivative), QRS12energy (trailing front of R—1st derivative), QRS2energy (R-wave as a  
117 whole—2nd derivative), TE1 (T-wave as a whole) - (the integral is calculated as the sum of  
118 energies at all points of the corresponding region );
- 119 • spectral integral set by the frequency grid 2 to 4 Hz, 4 to 8 Hz (QRSE1, QRSE2);
- 120 • frequency of the maximum energy of the leading and trailing fronts of the R wave (RonsF,  
121 RoffsF);
- 122 • rhythm variability (SDNN);
- 123 • ECG time markers: PpeakN, Rpeak, Speak, Tpeak, Tons, Toffs.

124 ECG time intervals were calculated not from the beginning of the cardiac cycle, but from a  
125 point on the isoline, two-thirds of the duration of the mean R-R interval from the previous R-  
126 wave (so called—Calculated point). All parameters, except for the indicators of rhythm  
127 variability, were averaged taking into account the pulse rate. Rhythm variability indicators  
128 were evaluated by the program without averaging the values. Thus, the time parameters of the  
129 ECG took into account not only the morphology of the cardiac cycle, but also changes the  
130 heart rate. Considering that averaged values were taken into account, a longer recording  
131 provides the most accurate parameters. This includes markers of the beginning or the end of  
132 the wave (Pfi, QRSst, QRSfi), the shift of the negative or positive maximum value relative to  
133 the beginning of the averaged complex (PpeakN, Rpeak, Speak, Tpeak), as well as the  
134 maximum slope of the waves (Tons, Toffs). QRSfi is the time interval from the calculated  
135 point to the end of the QRS complex, expressed in ms. Tpeak is the time interval from the

136 calculated point to the peak of the T wave. Toffs is the time interval from the calculated point  
137 to the point of maximum steepness of the descending knee of the T wave [2].

138 Taking into account that the position of the calculated point depends on the R-R interval, it is  
139 possible to minimize the effect of heart rate on the time parameters of the cardiac cycle.  
140 These time parameters take into account not only the morphology of the QRS complex or T-  
141 wave, but also the temporal features of the entire cardiac cycle.

142 After logistic regression analysis including more than 200 ECG parameter listed above, the  
143 artificial intelligence method was used to find combinations with the highest accuracy for  
144 IHD determination.

#### 145 **Criteria for the study participants**

146 The inclusion criteria included;

- 147 1. Participants age  $\geq$  40 years.
- 148 2. Participants with intact mental and physical activity.
- 149 3. Written consent to participate in the study, take blood samples, and anonymously  
150 publish the results of the study.
- 151 4. The participants of the control group are individuals without coronary artery disease,  
152 confirmed by the absence of the myocardial perfusion defect on the adenosine  
153 triphosphate stress myocardial perfusion computed tomography ((by using contrast  
154 enhanced multi-slice spiral computed tomography (CE-MSCT) using adenosine  
155 triphosphate (ATP)), and confirmed by medical history, previous medical tests, and  
156 retrospective interview of participants.
- 157 5. The participants of the experimental group are individuals with coronary artery  
158 disease, confirmed by myocardial perfusion defect on the adenosine triphosphate  
159 stress myocardial perfusion computed tomography, and confirmed by medical history,  
160 previous medical tests, and retrospective interview of participants.

161 Exclusion criteria:

- 162 1. Poor single-channel ECG and pulse wave recording quality
- 163 2. Failure of the stress test for reasons unrelated to heart disease
- 164 3. Reluctance to continue participating in the study.

165 Non-inclusion criteria

- 166 1. Pregnancy.
- 167 2. Diabetes mellitus
- 168 3. Presence of signs of acute coronary syndrome (myocardial infarction in the last two  
169 days), history of myocardial infarction;

- 170 4. Active infectious and non-infectious inflammatory diseases in the exacerbation phase;  
171 5. Respiratory diseases (bronchial asthma, chronic bronchitis, cystic fibrosis);  
172 6. Acute thromboembolism of pulmonary artery branches;  
173 7. Aortic dissection;  
174 8. Critical heart defects;  
175 9. Active oncopathology;  
176 10. Decompensation phase of acute heart failure;  
177 11. Neurological pathology (Parkinson's disease, multiple sclerosis, acute psychosis,  
178 Guillain-Barré syndrome);  
179 12. Cardiac arrhythmias that do not allow exercise ECG testing (Wolff-Parkinson-White  
180 syndrome, Sick sinus syndrome, AV block of II-III-degree, persistent ventricular  
181 tachycardia);  
182 13. Diseases of the musculoskeletal system that prevent passing a stress test (bicycle  
183 ergometry);  
184 14. Allergic reaction to iodine and/or adenosine triphosphate.

185 **Data collection**

186 All participants at rest pass registration of S-ECG and pulse wave before (during 3 minutes)  
187 and just after (during 3 minutes) physical stress test (bicycle ergometry) using a portable  
188 single-channel recorder (Cardio-Qvark; Russia, Moscow) [3]. The S-ECG and pulse wave  
189 results interpreted using machine learning models developed by the Sechenov University  
190 team [3,4].

191 Both groups pass a vessel stiffness test and pulse wave recording as well as vascular age by  
192 using Fukuda Denshi device (VaSera VS-1500; Japan). Cuffs placed to assess the vascular  
193 stiffness (CAVI parameter) and the vascular age as well as the ankle-brachial index. [5]

194 Subsequently, participants pass exercise bicycle ergometry test (SCHILLER CS200 device;  
195 Bruce protocol or modified Bruce protocol). According to the results metabolic equivalent;  
196 Mets-BT (BT), the angina functional class (FC) in participants with positive stress test results  
197 will be determined. During the bicycle ergometry, the participants monitored with 12-lead  
198 ECG and manual blood pressure measurement, 1 time each 2 minutes. The rest time ECG  
199 and blood pressure monitoring continue for at least five minutes after the end of the stress  
200 bicycle ergometry test.

201 The procedure discontinues if: an increase in systolic blood pressure  $\geq 220$  mmHg,  
202 horizontal or down sloping ST segment depression on the ECG  $\geq 1$  mm, typical heart pain  
203 during test, ventricular tachycardia or atrial fibrillation, or other significant heart rhythm

204 disorders were found. Moreover, stop the procedure if the target heart rate (86% of the 220-  
205 age) is reached.

206 Before performing CE-MSCT, all the participants present results of the venous creatinine  
207 level, eGFR (estimated glomerular filtration rate) according to the 2021 CKD-EPI Creatinine  
208 > 30 ml/min/1,73 m<sup>2</sup>, according to the recommendation for using this formula by the  
209 National kidney foundation and the American Society of Nephrology [6–9].

210 The participants of both groups got catheterization in the basilar vein or the radial vein for  
211 injection of contrast and ATP to performed pharmacological stress test to the heart by  
212 increasing heart rate during the stressed myocardial perfusion computer tomography imaging.  
213 Computer tomography was performed on Canon scanner with 640 slice, 0,5 mm thickness of  
214 slice, with contrast (Omnipaque, 50 ml), injected two times: in rest to get images for  
215 myocardial perfusion before test, and in 20 mints just after ATP had been injected in dose  
216 according to body weight.

217 The results of the myocardial perfusion considered positive if there was a perfusion defect  
218 after stress test or worsen the already existing at the rest phase perfusion defect.

219 Statistical processing was carried out using the R programming language v4.2 and Python  
220 v.3.10 [R] [10,11].

### 221 **Statistical analysis**

222 For quantitative parameters, the nature of the distribution (using the Shapiro-Wilk test), the  
223 mean, the standard deviation, the median, the interquartile, the 95% confidence interval, the  
224 minimum and maximum values were determined. For categorical and qualitative features, the  
225 proportion and absolute number of values were determined.

226 Comparative analysis for normally distributed quantitative traits was carried out on the basis  
227 of Welch's t-test (2 groups); for abnormally distributed quantitative traits, using the Mann-  
228 Whitney U-test (2 groups).

229 Comparative analysis of categorical and qualitative features was carried out using the Pearson  
230 X-square criterion, in case of its inapplicability, using the exact Fisher test.

231 For Single channel ECG values, pre-load values (prefixed with " *q0\_*" were used, and deltas  
232 between immediately after exertion (*q1*) and after 2nd single channel ECG record, were  
233 calculated:

234

*q0 = before*

*q1 = after 1*

235 Calculation of deltas:

$$dltq_{01} = q1 - q0$$

### 236 **Outcome and feature selection**

237 In order to assess the impact of factors on outcomes due to the small number of observations,  
238 it was decided to abandon the classic univariate and subsequent stepwise or multivariate  
239 regression analysis. The effect of exhaled air and Cardio-Qvark on the target variable was  
240 assessed using a mathematical modeling conveyor.

241 Due to the small number of observations, the so-called external cross-validation was used to  
242 assess the model's performance to select predictors. Selection was made among the predictor  
243 levels before the sample (Cardio-Qvark results), and then the delta for Cardio-Qvark results,  
244 as calculated above.

245 The data was randomly split with a mixing procedure into 3 parts. Each part became a  
246 validation array, and the remaining 2/3 became a training array. Thus, 3 different models  
247 were trained on each iteration, and none of the models were validated on the same data as  
248 they were trained.

249 This iteration was repeated 500 times with different options for splitting the data into 3 parts  
250 [12]. This approach allows us to draw indirect conclusions about the possibility of  
251 generalizing the results of model quality into larger samples.

252 The purpose of this method was to select the predictors with the highest normalized  
253 coefficients for each constructed model, which was a logistic regression with L1  
254 regularization (Lasso regression). For each model that showed the quality of the AUC  
255 classifier above 0.75 in the validation part of the sample, the selected predictors and the  
256 corresponding coefficients were taken. For each predictor, the coefficients were taken  
257 modulo, then averaged, after which the 5 predictors with the highest coefficients were used  
258 for subsequent validation.

259 The validation process consisted of using only 5 selected predictors to build the model. In  
260 other respects, 3-fold cross-validation with data mixing with subsequent evaluation of the  
261 results of 3 classifiers was also used. This was possible because the hyperparameters of the  
262 classifiers were the same, and all 3 validation samples together gave all the data in the total  
263 sample.

### 264 **Results**

265 The characteristics of the sample described in the tables bellow. (*Table 1A-B*)

266 Table 1A: Categorical variables presented in absolute and relative values of the study for true  
267 incidence of the stated factor. Abbreviations: CPT; stress myocardial perfusion computer



268 tomography imaging.  $X^2$  test used as a comparative test. \* Values statically significant  
 269 difference. Abbreviations: METs; metabolic equivalent.

Index	Factor	Group 1 (n=19). Positive CTP	Group 2 (n=19). Negative CTP	p
Gender	F	10 (52.6%)	7 (36.8%)	0.328
	M	9 (47.4%)	12 (63.2%)	
Obesity stage	1 degree	3 (15.8%)	3 (15.8%)	>0.99
	Normal	8 (42.1%)	9 (47.4%)	
	Overweight	8 (42.1%)	7 (36.8%)	
Atherosclerotic vascular (Namely)	Carotid	1 (9.1%)	0 (0.0%)	>0.99
	Carotid. Brachiocephalic bifurcation	10 (90.9%)	4 (100.0%)	
Stage of hypertension	I	2 (25.0%)	1 (7.1%)	0.179
	II	3 (37.5%)	11 (78.6%)	
	III	3 (37.5%)	2 (14.3%)	
Degree of hypertension	Degree 1	4 (50.0%)	7 (50.0%)	0.366
	Degree 2	1 (12.5%)	5 (35.7%)	
	Degree 3	3 (37.5%)	2 (14.3%)	
Risk of cardiovascular disease	High	3 (15.8%)	7 (36.8%)	0.486
	Low	7 (36.8%)	4 (21.1%)	
	Moderate	7 (36.8%)	7 (36.8%)	
	Very high	2 (10.5%)	1 (5.3%)	
Blood pressure reaction type	Asthenic	2 (10.5%)	1 (5.3%)	0.30

on stress test				2
	Hypertonic	1 (5.3%)	1 (5.3%)	
	Hypotonic	3 (15.8%)	0 (0.0%)	
	Mild Hypertonic	1 (5.3%)	1 (5.3%)	
	Normotonic	12 (63.2%)	16 (84.2%)	
Watt	75	4 (21.1%)	7 (36.8%)	0.167
	100	8 (42.1%)	2 (10.5%)	
	125	4 (21.1%)	3 (15.8%)	
	150	1 (5.3%)	2 (10.5%)	
	175	0 (0.0%)	2 (10.5%)	
	200	1 (5.3%)	3 (15.8%)	
	250	1 (5.3%)	0 (0.0%)	
Functional class by Watt	FC-I	2 (40.0%)	3 (42.9%)	>0.99
	FC-II	3 (60.0%)	4 (57.1%)	
Functional class by METs	FC-I	1 (20.0%)	3 (42.9%)	0.735
	FC-II	4 (80.0%)	3 (42.9%)	
	FC-III	0 (0.0%)	1 (14.3%)	
Reaction type to stress test (positive/negative)	Negative	8 (42.1%)	9 (47.4%)	0.593
	Positive	5 (26.3%)	7 (36.8%)	
	Suspected	6 (31.6%)	3 (15.8%)	
Reason of discontinuation of the stress test	Horizontal ST depression >1mm	2 (10.5%)	4 (21.1%)	0.660
	Reach	17 (89.5%)	15 (78.9%)	

	goal HR			
Tolerance to exertion on stress test	Close to high	2 (10.5%)	2 (10.5%)	0.830
	High	2 (10.5%)	2 (10.5%)	
	Low	0 (0.0%)	1 (5.3%)	
	Moderate	13 (68.4%)	10 (52.6%)	
	Very high	2 (10.5%)	4 (21.1%)	
Biological estimated vascular age	High	10 (52.6%)	9 (47.4%)	0.746
	Normal	9 (47.4%)	10 (52.6%)	
CKD stage	I	6 (31.6%)	10 (52.6%)	0.078
	II	9 (47.4%)	9 (47.4%)	
	IIIa	4 (21.1%)	0 (0.0%)	

270

271 Table 1B: The continuous variables of the sample presented as a mean  $\pm$  standard deviation  
272 (Std. div.), Student test as independent variables used. \* Values statically significant  
273 difference. Abbreviations: SBP; systolic blood pressure, DBP; diastolic blood pressure, BMI,  
274 body mass index, HR; heart rate, METs; metabolic equivalent, R-CAVI; right Cardio-ankle  
275 vascular index, L-CAVI; left Cardio-ankle vascular index, RABI; right ankle-brachial index,  
276 LABI; left ankle-brachial index, SBP B; systolic blood pressure brachial, DBP B; diastolic  
277 blood pressure brachial, BP RB; blood pressure right brachial, BP RA ; blood pressure right  
278 ankle, BP LA; blood pressure left ankle, BP A; blood pressure ankle, ABI; ankle-brachial  
279 index, RTb; right brachial pulse, LTb; left brachial pulse, Tb; mean brachial pulse, Tba; mean  
280 brachial-ankle pulse, Lha (cm); length heart-ankle, haPWV (m/s); heart-ankle pulse wave  
281 velocity.

Index	Group 1 (n=19). Positive CTP. Mean $\pm$ Std. div.	Group 2 (n=19). Negative CTP. Mean $\pm$ Std. div.	p
Age	56.9 $\pm$ 6.2	60.6 $\pm$ 12.1	0.238
Pulse rest	73.2 $\pm$ 9.6	71.3 $\pm$ 11.1	0.578
SBP rest	124.4 $\pm$ 9.4	120.6 $\pm$ 14.8	0.3

			54
DBP rest	79.1 ± 11.1	76.6 ± 8.2	0.4 29
Body weight	77.8 ± 17.4	74.0 ± 10.6	0.4 18
Height	173.2 ± 10.3	169.4 ± 8.9	0.2 40
BMI	25.8 ± 4.3	25.9 ± 4.1	0.9 39
Goal heart rate (HR)	163.1 ± 6.2	159.4 ± 12.1	0.2 38
Maximum HR	149.5 ± 11.2	146.7 ± 19.7	0.7 48
Reached % of the target HR on stress test	91.8 ± 8.2	92.6 ± 14.9	0.6 65
METs	6.7 ± 2.0	6.5 ± 2.1	0.7 15
Ejection fraction (%)	64.6 ± 4.1	65.3 ± 5.4	0.7 26
Biological estimated vessel age	58.1 ± 7.6	62.6 ± 13.9	0.2 22
R-CAVI	8.5 ± 0.8	9.1 ± 1.8	0.2 92
L-CAVI	8.5 ± 0.7	9.0 ± 1.7	0.2 31
RABI	1.2 ± 0.1	1.1 ± 0.1	0.1 81
LABI	1.2 ± 0.1	1.1 ± 0.1	0.0 82
Mean SBP B	130.1 ± 8.7	133.2 ± 16.2	0.4 65
Mean DBP B	82.9 ± 8.4	83.5 ± 9.0	0.8 17

BP RB $(=(SBP+DBP)/2)$	$100.7 \pm 10.0$	$102.8 \pm 14.0$	0.5 89
BP LB $(=(SBP+DBP)/2)$	$101.8 \pm 10.6$	$103.7 \pm 12.7$	0.6 31
Mean BP B= $(BP RB + BP LB)/2$	$101.3 \pm 10.1$	$103.3 \pm 13.2$	0.6 03
BP RA $(=(SBP+DBP)/2)$	$105.3 \pm 10.7$	$108.3 \pm 14.1$	0.4 73
BP LA $(=(SBP+DBP)/2)$	$106.6 \pm 9.6$	$106.9 \pm 11.1$	0.9 26
Mean BP A= $(BP RA + BP LA)/2$	$106.0 \pm 9.6$	$107.6 \pm 12.1$	0.6 47
Mean ABI= $(RABI+LABI)/2$	$1.2 \pm 0.1$	$1.1 \pm 0.1$	0.1 01
RTb	$79.4 \pm 8.9$	$78.7 \pm 11.5$	0.8 39
LTb	$73.3 \pm 6.5$	$74.8 \pm 10.7$	0.5 99
Mean Tb = $(RTb + LTb)/2$	$76.3 \pm 7.0$	$76.8 \pm 10.8$	0.8 88
Right Tba	$88.5 \pm 10.9$	$77.4 \pm 22.1$	0.1 25
Left Tba	$87.7 \pm 9.0$	$79.0 \pm 20.8$	0.1 44
Mean Tba = $(Right Tba + Left Tba)/2$	$88.1 \pm 9.8$	$78.2 \pm 21.3$	0.1 29
Lha (cm)	$150.8 \pm 8.4$	$147.7 \pm 7.2$	0.2 40
haPWV (m/s)	$0.9 \pm 0.1$	$1.0 \pm 0.2$	0.2 34
$\beta$ -stiffness index from PWV	$3.0 \pm 0.6$	$3.3 \pm 1.2$	0.6 86
Creatinine ( $\mu$ mol/L)	$83.9 \pm 11.9$	$86.4 \pm 19.4$	0.6

			36
eGFR (2021 CKD-EPI Creatinine)	84.5 ± 13.7	79.6 ± 17.4	0.3 45

282 **The diagnostic accuracy of the bicycle ergometry**

283 We examined the diagnostic accuracy of a standard exercise test on a bicycle ergometer. In  
 284 the ROC analysis, where the predictor was the result of a sample with the results of the  
 285 physical exertion “Reaction\_type” = 'Positive', and the target variable was  
 286 Myocardial\_perfusion\_defect\_after\_stress\_ATP, the following results were obtained. (Table  
 287 2)

288 Table 2: The quality of the bicycle ergometry appeared quite low in our cohort.

Chars	Point estimate	95%CI
AUC	0.553	[0.406 0.695]
Sensitivity	0.263	[0.067 0.474]
Specificity	0.632	[0.409 0.833]
Negative predictive value	0.462	[0.269 0.654]
Positive predictive value	0.417	[0.143 0.714]

289

290 **Cardio-Qvark Feature selection with cross-validation**

291 After performing pipeline for feature selection using 500 iterations with 3-fold outer cross-  
 292 validation , 87 best models were selected, showing  $AUC \geq 0.9$  for the test set. All models  
 293 were aggregated with their respective absolute coefficients, and then the median estimate of  
 294 the coefficients for each feature was calculated. Below are the selected 20 predictors (the  
 295 final model included the first 5). (Table 3)

296 Table 3: The 20 most statically significant features according to the build model. Dltq\_01  
 297 indicates the difference between the selected single channel ECG features immediately after  
 298 the stress minus the selected features before the stress test.

	Feature	Lasso absolute coefficient
1.	<b>dltq_01_Pan...31</b>	0.589804
2.	<b>dltq_01_SA</b>	0.509832
3.	<b>dltq_01_JA</b>	0.37366

4.	<b>dltq_01_TE1</b>	0.270038
5.	<b>dltq_01_TpTe</b>	0.258854
6.	<b>dltq_01_HFNoise</b>	0.248446
7.	<b>dltq_01_PpeakN</b>	0.206324
8.	<b>dltq_01_QRS1energy</b>	0.190459
9.	<b>dltq_01_TA</b>	0.15963
10.	<b>dltq_01_Sbeta</b>	0.150864
11.	<b>dltq_01_TE3</b>	0.138504
12.	<b>dltq_01_Tenergy</b>	0.125174
13.	<b>dltq_01_TE4</b>	0.116375
14.	<b>dltq_01_Tpenergy</b>	0.106516
15.	<b>dltq_01_QTc</b>	0.102957
16.	<b>dltq_01_TE2</b>	0.102495
17.	<b>dltq_01_HFQRS</b>	0.090197
18.	<b>dltq_01_SDNN</b>	0.082806
19.	<b>dltq_01_QRSE1</b>	0.082143
20.	<b>dltq_01_QRSw</b>	0.063462

299

300 The model was then rebuilt as follows. The top 5 predictors from *Table 3* were with the most  
301 mathematical importance according to the built model taken and included in the new  
302 LASSO regression model.

303 Then the leave-one-out cross-validation procedure was performed, which allowed us to  
304 obtain approximate estimates of sensitivity, specificity, positive and negative prognostic  
305 value. At each iteration of leave-one-out cross-validation , the quantitative predictors were  
306 normalized.

307 The quality of the classification is shown in the table below. (*Table 4*)


308 Table 4: The quality of the single channel ECG in the diagnosis of ischemic heart disease  
309 using the Cardio-Qvark.

Chars	Point estimate	95%CI
AUC	0.684	[0.527 ; 0.817]
Sensitivity	0.737	[0.533 ; 0.929]
Specificity	0.632	[0.391 ; 0.833]
Negative	0.706	[0.47 ; 0.917]

predictive value		
Positive predictive value	0.667	[0.444 ; 0.857]

310

311 Confidence results are calculated using a bootstrap. Due to the small number of observations,  
 312 the 95% CI is quite wide. Comparison with load results was carried out using the McNemar  
 313 test [13].



314

315 Figure 1: There is a significant difference between the results of the load test and the built  
 316 model, obviously, the model has better predictive properties, P value = 0.0001.

317



318 The comparative statistical analysis demonstrated that the dltq\_01\_TpTe parameter has a  
319 statically significant difference between the two groups, in the first group, the mean  $\pm$  Std.  
320 Div.  $7.2 \pm 28.1$ , and in the second group, the mean  $\pm$  Std. Div.  $-12.2 \pm 20.0$ , p value=0.046.

### 321 **Discussion**

322 Using physical stress tested monitored 12 lead-ECG remains the elementary test for the  
323 primary detection of ischemic heart disease. However, severe limitations exist in the  
324 diagnostic accuracy related to the ECG artifact during the movement of the patients during  
325 the physical stress test.

326 The following Cardio-Qvark parameter are of interest for further investigation to reveal the  
327 hidden diagnostic value in the diagnosis of ischemic heart disease, dltq\_01\_Pan...31,  
328 dltq\_01\_SA, dltq\_01\_JA, dltq\_01\_TE1, and dltq\_01\_TpTe. Further, study on a larger sample  
329 is ongoing on clinicaltrials.gov (NCT06181799).

### 330 **Conclusions**

331 Single channel ECG (Cardio-Qvark) have a potential to be used as an additional method for  
332 the diagnosis of ischemic heart disease in combination with the physical stress test including  
333 bicycle ergometry. Further studies required on a larger sample size needed to confirm the  
334 usage of the Cardio-Qvark for the clinical use for the diagnosis of ischemic heart disease.

### 335 **List of abbreviations**

336 CVD; cardiovascular disease, CTP; stress computed tomography myocardial perfusion  
337 imaging

### 338 **Decelerations**

- 339 1. Ethics approval and consent to participate: the study approved by the Sechenov  
340 University, Russia, from “Ethics Committee Requirement № 19-23 from 26.10.2023”.  
341 A written consent is taken from the study participants
- 342 2. Consent for publication: applicable on reasonable request
- 343 3. Availability of data and materials: applicable on reasonable request
- 344 4. Competing interests: The authors declare that they have no competing interests  
345 regarding publication.
- 346 5. Funding’s: The work financed by the Ministry of Science and Higher Education of the  
347 Russian Federation within the framework of state support for the creation and  
348 development of World-Class Research Center ‘Digital biodesign and personalized  
349 healthcare’ № 075-15-2022-304.
- 350 6. Authors' contributions: MB is the writer, researcher, collected and analyzed data,  
351 interpreted the results, and revised the final version of the manuscript, MA, collected

352 part of the patients, AS analyzed the exhaled breath, AS biostatistical analysis of the  
353 sample, PCh, DG, NV, NM, AAB, SVK, EF, revised the paper, and PhK revised the  
354 final version of the manuscript. All authors have read and approved the manuscript.

355 7. Acknowledgments: not applicable

356 8. Authors' information: **Basheer Abdullah Marzoog**, World-Class Research Center  
357 «Digital Biodesign and Personalized Healthcare», I.M. Sechenov First Moscow State  
358 Medical University (Sechenov University), 119991 Moscow, Russia; postal address:  
359 Russia, Moscow, 8-2 Trubetskaya street, 119991. (marzug@mail.ru, +79969602820).  
360 ORCID: 0000-0001-5507-2413. Scopus ID: 57486338800. **Magomed Abdullaev**,  
361 World-Class Research Center «Digital Biodesign and Personalized Healthcare», I.M.  
362 Sechenov First Moscow State Medical University (Sechenov University), 119991  
363 Moscow, Russia; postal address: Russia, Moscow, 8-2 Trubetskaya street, 119991.  
364 ORCID: 0000-0002-0451-2009. email: m.ba.m@icloud.com. **Peter Chomakhidze**,  
365 World-Class Research Center «Digital Biodesign and Personalized Healthcare», I.M.  
366 Sechenov First Moscow State Medical University (Sechenov University), 119991  
367 Moscow, Russia; postal address: Russia, Moscow, 8-2 Trubetskaya street, 119991.  
368 ORCID: 0000-0003-1485-6072. email: m.ba.m@bk.ru. **Daria Gognieva**, World-Class  
369 Research Center «Digital Biodesign and Personalized Healthcare», I.M. Sechenov First  
370 Moscow State Medical University (Sechenov University), 119991 Moscow, Russia;  
371 postal address: Russia, Moscow, 8-2 Trubetskaya street, 119991. ORCID: 0000-0002-  
372 0451-2009. email: gognievad\_g@staff.sechenov.ru. **Nina Vladimirovna Gagarina**,  
373 University clinical Hospital number 1, Radiology department, I.M. Sechenov First  
374 Moscow State Medical University (Sechenov University), 119991 Moscow, Russia;  
375 postal address: Russia, Moscow, 8-2 Trubetskaya street, 119991. Scopus ID:  
376 6508312251. m.ba98@bk.ru. **Natalia Mozzhukhina**, University clinical Hospital  
377 number 1, Radiology department, I.M. Sechenov First Moscow State Medical  
378 University (Sechenov University), 119991 Moscow, Russia; postal address: Russia,  
379 Moscow, 8-2 Trubetskaya street, 119991. ORCID: 0009-0002-7334-6945.  
380 v.t.i.m.b@outlook.com. **Sergey Vladimirovich Kostin**, National Research Ogarev  
381 Mordovia State University. Russia, Republic of Mordovia, Saransk, Bolshevistskaya  
382 str., 68, Saransk, Mordovia Republic, 430005. email: dr.mosalah@mail.ru. **Alexander**  
383 **Suvorov**, World-Class Research Center «Digital Biodesign and Personalized  
384 Healthcare», I.M. Sechenov First Moscow State Medical University (Sechenov  
385 University), 119991 Moscow, Russia; postal address: Russia, Moscow, 8-2 Trubetskaya

386 street, 119991. email: [suvorovayul@staff.sechenov.ru](mailto:suvorovayul@staff.sechenov.ru). **Afina Aftandilovna**  
387 **Bestavashvili**, World-Class Research Center «Digital Biodesign and Personalized  
388 Healthcare», I.M. Sechenov First Moscow State Medical University (Sechenov  
389 University), 119991 Moscow, Russia; postal address: Russia, Moscow, 8-2 Trubetskaya  
390 street, 119991. email: [basheermarzoog1998@gmail.com](mailto:basheermarzoog1998@gmail.com). **Ekaterina Fominykha**,  
391 University clinical Hospital number 1, Radiology department, I.M. Sechenov First  
392 Moscow State Medical University (Sechenov University), 119991, Moscow, Russia;  
393 postal address: Russia, Moscow, 8-2 Trubetskaya street, 119991. ORCID: 0000-0003-  
394 0288-7656. Email: [Fominykhev@staff.sechenov.ru](mailto:Fominykhev@staff.sechenov.ru). **Philipp Kopylov**, director of the  
395 institute of the Research Center «Digital Biodesign and Personalized Healthcare», I.M.  
396 Sechenov First Moscow State Medical University (Sechenov University), 119991  
397 Moscow, Russia; postal address: Russia, Moscow, 8-2 Trubetskaya street, 119991.  
398 ORCID: 0000-0002-4535-8685. Scopus ID: 6507736224. email:  
399 [kopylovf\\_yu@staff.sechenov.ru](mailto:kopylovf_yu@staff.sechenov.ru)

400 9. The paper has not been submitted elsewhere

401

## 402 **STANDARDS OF REPORTING**

403 STROBE guideline has been followed.

404

## 405 **References**

- 406 [1] B.A. Marzoog, Breathomics Detect the Cardiovascular Disease: Delusion or Dilution  
407 of the Metabolomic Signature., *Curr. Cardiol. Rev.* 20 (2024).  
408 <https://doi.org/10.2174/011573403X283768240124065853>.
- 409 [2] N. Kuznetsova, A. Gubina, Z. Sagirova, I. Dhif, D. Gognieva, A. Melnichuk, O. Orlov,  
410 E. Syrkin, V. Sedov, P. Chomakhidze, H. Saner, P. Kopylov, Left Ventricular  
411 Diastolic Dysfunction Screening by a Smartphone-Case Based on Single Lead ECG,  
412 *Clin. Med. Insights Cardiol.* 16 (2022). <https://doi.org/10.1177/11795468221120088>.
- 413 [3] D. Gognieva, N. Vishnyakova, Y. Mitina, P. Chomakhidze, D. Mesitskaya, N.  
414 Kuznetsova, M. Khiari, G. Ryabykina, S. Boytsov, A. Syrkin, H. Saner, P. Kopylov,  
415 Remote Screening for Atrial Fibrillation by a Federal Cardiac Monitoring System in  
416 Primary Care Patients in Russia: Results from the Prospective Interventional  
417 Multicenter FECAS-AFS Study, *Glob. Heart.* 17 (2022).  
418 <https://doi.org/10.5334/gh.1057>.
- 419 [4] Z. Sagirova, N. Kuznetsova, N. Gogiberidze, D. Gognieva, A. Suvorov, P.

420 Chomakhidze, S. Omboni, H. Saner, P. Kopylov, Cuffless Blood Pressure  
421 Measurement Using a Smartphone-Case Based ECG Monitor with  
422 Photoplethysmography in Hypertensive Patients, *Sensors*. 21 (2021) 3525.  
423 <https://doi.org/10.3390/s21103525>.

424 [5] K. Shirai, N. Hiruta, M. Song, T. Kurosu, J. Suzuki, T. Tomaru, Y. Miyashita, A.  
425 Saiki, M. Takahashi, K. Suzuki, M. Takata, Cardio-ankle vascular index (CAVI) as a  
426 novel indicator of arterial stiffness: theory, evidence and perspectives., *J. Atheroscler.*  
427 *Thromb.* 18 (2011) 924–938. <https://doi.org/10.5551/jat.7716>.

428 [6] D.W. Cockcroft, M.H. Gault, Prediction of creatinine clearance from serum  
429 creatinine., *Nephron*. 16 (1976) 31–41. <https://doi.org/10.1159/000180580>.

430 [7] M.A. Winter, K.N. Guhr, G.M. Berg, Impact of various body weights and serum  
431 creatinine concentrations on the bias and accuracy of the Cockcroft-Gault equation.,  
432 *Pharmacotherapy*. 32 (2012) 604–12. [https://doi.org/10.1002/j.1875-](https://doi.org/10.1002/j.1875-9114.2012.01098.x)  
433 [9114.2012.01098.x](https://doi.org/10.1002/j.1875-9114.2012.01098.x).

434 [8] D.L. Brown, A.J. Masselink, C.D. Lalla, Functional range of creatinine clearance for  
435 renal drug dosing: a practical solution to the controversy of which weight to use in the  
436 Cockcroft-Gault equation., *Ann. Pharmacother.* 47 (2013) 1039–44.  
437 <https://doi.org/10.1345/aph.1S176>.

438 [9] C. Delgado, M. Baweja, D.C. Crews, N.D. Eneanya, C.A. Gadegbeku, L.A. Inker,  
439 M.L. Mendu, W.G. Miller, M.M. Moxey-Mims, G. V. Roberts, W.L. St. Peter, C.  
440 Warfield, N.R. Powe, A Unifying Approach for GFR Estimation: Recommendations of  
441 the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney  
442 Disease, *Am. J. Kidney Dis.* 79 (2022) 268-288.e1.  
443 <https://doi.org/10.1053/j.ajkd.2021.08.003>.


444 [10] Z.N. Sagirova, N.O. Kuznetsova, A.Y. Suvorov, D.G. Gognieva, V.M. Kulikov, P.S.  
445 Chomakhidze, D.A. Andreev, P.Y. Kopylov, Assessment of left ventricular systolic  
446 function using a single-channel ECG monitor with photoplethysmography based on  
447 machine learning models, *Kardiol. i Serdechno-Sosudistaya Khirurgiya*. 16 (2023) 46.  
448 <https://doi.org/10.17116/kardio20231601146>.

449 [11] N. Kuznetsova, Z. Sagirova, A. Suvorov, I. Dhif, D. Gognieva, B. Afina, M.  
450 Poltavskaya, V. Sedov, P. Chomakhidze, P. Kopylov, A screening method for  
451 predicting left ventricular dysfunction based on spectral analysis of a single-channel  
452 electrocardiogram using machine learning algorithms, *Biomed. Signal Process.*  
453 *Control*. 86 (2023) 105219. <https://doi.org/10.1016/j.bspc.2023.105219>.

454 [12] G.C. Cawley, N.L.C. Talbot, On Over-fitting in Model Selection and Subsequent  
455 Selection Bias in Performance Evaluation, *J. Mach. Learn. Res.* 11 (2010) 2079–2107.  
456 [13] O.U. Marius, O.-I. Happiness, An extended McNemar test for comparing correlated  
457 proportion of positive responses, *Biometrics Biostat. Int. J.* 8 (2019) 125–137.  
458 <https://doi.org/10.15406/bbij.2019.08.00281>.

459

460 **Figure legends**



461

462 Figure 2: There is a significant difference between the results of the load test and the built  
463 model, obviously, the model has better predictive properties, P value = 0.0001.

464

465

466 **Table legends**

467 Table 5A: Categorical variables presented in absolute and relative values of the study for true  
 468 incidence of the stated factor. Abbreviations: CPT; stress myocardial perfusion computer  
 469 tomography imaging.  $X^2$  test used as a comparative test. \* Values statically significant  
 470 difference. Abbreviations: METs; metabolic equivalent.

Index	Factor	Group 1 (n=19). Positive CTP	Group 2 (n=19). Negative CTP	p
Gender	F	10 (52.6%)	7 (36.8%)	0.328
	M	9 (47.4%)	12 (63.2%)	
Obesity stage	1 degree	3 (15.8%)	3 (15.8%)	>0.999
	Normal	8 (42.1%)	9 (47.4%)	
	Overweight	8 (42.1%)	7 (36.8%)	
Atherosclerotic vascular (Namely)	Carotid	1 (9.1%)	0 (0.0%)	>0.999
	Carotid. Brachiocephalic bifurcation	10 (90.9%)	4 (100.0%)	
Stage of hypertension	I	2 (25.0%)	1 (7.1%)	0.179
	II	3 (37.5%)	11 (78.6%)	
	III	3 (37.5%)	2 (14.3%)	
Degree of hypertension	Degree 1	4 (50.0%)	7 (50.0%)	0.366
	Degree 2	1 (12.5%)	5 (35.7%)	
	Degree 3	3 (37.5%)	2 (14.3%)	
Risk of cardiovascular disease	High	3 (15.8%)	7 (36.8%)	0.486
	Low	7 (36.8%)	4 (21.1%)	

	Moderate	7 (36.8%)	7 (36.8%)	
	Very high	2 (10.5%)	1 (5.3%)	
Blood pressure reaction type on stress test	Asthenic	2 (10.5%)	1 (5.3%)	0.30 2
	Hypertonic	1 (5.3%)	1 (5.3%)	
	Hypotonic	3 (15.8%)	0 (0.0%)	
	Mild Hypertonic	1 (5.3%)	1 (5.3%)	
	Normotonic	12 (63.2%)	16 (84.2%)	
Watt	75	4 (21.1%)	7 (36.8%)	0.16 7
	100	8 (42.1%)	2 (10.5%)	
	125	4 (21.1%)	3 (15.8%)	
	150	1 (5.3%)	2 (10.5%)	
	175	0 (0.0%)	2 (10.5%)	
	200	1 (5.3%)	3 (15.8%)	
	250	1 (5.3%)	0 (0.0%)	
Functional class by Watt	FC-I	2 (40.0%)	3 (42.9%)	>0.9 99
	FC-II	3 (60.0%)	4 (57.1%)	
Functional class by METs	FC-I	1 (20.0%)	3 (42.9%)	0.73 5
	FC-II	4 (80.0%)	3 (42.9%)	
	FC-III	0 (0.0%)	1 (14.3%)	
Reaction type to stress test (positive/negative)	Negative	8 (42.1%)	9 (47.4%)	0.59 3
	Positive	5 (26.3%)	7 (36.8%)	
	Suspected	6 (31.6%)	3 (15.8%)	
Reason of discontinuation of the stress test	Horizontal ST	2 (10.5%)	4 (21.1%)	0.66 0

	depression >1mm			
	Reach goal HR	17 (89.5%)	15 (78.9%)	
Tolerance to exertion on stress test	Close to high	2 (10.5%)	2 (10.5%)	0.83 0
	High	2 (10.5%)	2 (10.5%)	
	Low	0 (0.0%)	1 (5.3%)	
	Moderate	13 (68.4%)	10 (52.6%)	
	Very high	2 (10.5%)	4 (21.1%)	
Biological estimated vascular age	High	10 (52.6%)	9 (47.4%)	0.74 6
	Normal	9 (47.4%)	10 (52.6%)	
CKD stage	I	6 (31.6%)	10 (52.6%)	0.07 8
	II	9 (47.4%)	9 (47.4%)	
	IIIa	4 (21.1%)	0 (0.0%)	

471

472 Table 1B: The continuous variables of the sample presented as a mean  $\pm$  standard deviation  
473 (Std. div.), Student test as independent variables used. \* Values statically significant  
474 difference. Abbreviations: SBP; systolic blood pressure, DBP; diastolic blood pressure, BMI,  
475 body mass index, HR; heart rate, METs; metabolic equivalent, R-CAVI; right Cardio-ankle  
476 vascular index, L-CAVI; left Cardio-ankle vascular index, RABI; right ankle-brachial index,  
477 LABI; left ankle-brachial index, SBP B; systolic blood pressure brachial, DBP B; diastolic  
478 blood pressure brachial, BP RB; blood pressure right brachial, BP RA ; blood pressure right  
479 ankle, BP LA; blood pressure left ankle, BP A; blood pressure ankle, ABI; ankle-brachial  
480 index, RTb; right brachial pulse, LTb; left brachial pulse, Tb; mean brachial pulse, Tba; mean  
481 brachial-ankle pulse, Lha (cm); length heart-ankle, haPWV (m/s); heart-ankle pulse wave  
482 velocity.

Index	Group 1 (n=19). Positive CTP. Mean $\pm$ Std. div.	Group 2 (n=19). Negative CTP. Mean $\pm$ Std. div.	p
Age	56.9 $\pm$ 6.2	60.6 $\pm$ 12.1	0.2 38



Pulse rest	73.2 ± 9.6	71.3 ± 11.1	0.5 78
SBP rest	124.4 ± 9.4	120.6 ± 14.8	0.3 54
DBP rest	79.1 ± 11.1	76.6 ± 8.2	0.4 29
Body weight	77.8 ± 17.4	74.0 ± 10.6	0.4 18
Height	173.2 ± 10.3	169.4 ± 8.9	0.2 40
BMI	25.8 ± 4.3	25.9 ± 4.1	0.9 39
Goal heart rate (HR)	163.1 ± 6.2	159.4 ± 12.1	0.2 38
Maximum HR	149.5 ± 11.2	146.7 ± 19.7	0.7 48
Reached % of the target HR on stress test	91.8 ± 8.2	92.6 ± 14.9	0.6 65
METs	6.7 ± 2.0	6.5 ± 2.1	0.7 15
Ejection fraction (%)	64.6 ± 4.1	65.3 ± 5.4	0.7 26
Biological estimated vessel age	58.1 ± 7.6	62.6 ± 13.9	0.2 22
R-CAVI	8.5 ± 0.8	9.1 ± 1.8	0.2 92
L-CAVI	8.5 ± 0.7	9.0 ± 1.7	0.2 31
RABI	1.2 ± 0.1	1.1 ± 0.1	0.1 81
LABI	1.2 ± 0.1	1.1 ± 0.1	0.0 82
Mean SBP B	130.1 ± 8.7	133.2 ± 16.2	0.4

			65
Mean DBP B	82.9 ± 8.4	83.5 ± 9.0	0.8 17
BP RB $(=(SBP+DBP)/2)$	100.7 ± 10.0	102.8 ± 14.0	0.5 89
BP LB $(=(SBP+DBP)/2)$	101.8 ± 10.6	103.7 ± 12.7	0.6 31
Mean BP B= $(BP RB + BP LB)/2$	101.3 ± 10.1	103.3 ± 13.2	0.6 03
BP RA $(=(SBP+DBP)/2)$	105.3 ± 10.7	108.3 ± 14.1	0.4 73
BP LA $(=(SBP+DBP)/2)$	106.6 ± 9.6	106.9 ± 11.1	0.9 26
Mean BP A= $(BP RA + BP LA)/2$	106.0 ± 9.6	107.6 ± 12.1	0.6 47
Mean ABI= $(RABI+LABI)/2$	1.2 ± 0.1	1.1 ± 0.1	0.1 01
RTb	79.4 ± 8.9	78.7 ± 11.5	0.8 39
LTb	73.3 ± 6.5	74.8 ± 10.7	0.5 99
Mean Tb $=( RTb + LTb)/2$	76.3 ± 7.0	76.8 ± 10.8	0.8 88
Right Tba	88.5 ± 10.9	77.4 ± 22.1	0.1 25
Left Tba	87.7 ± 9.0	79.0 ± 20.8	0.1 44
Mean Tba $=( Right Tba + Left Tba)/2$	88.1 ± 9.8	78.2 ± 21.3	0.1 29
Lha (cm)	150.8 ± 8.4	147.7 ± 7.2	0.2 40
haPWV (m/s)	0.9 ± 0.1	1.0 ± 0.2	0.2 34

$\beta$ -stiffness index from PWV	$3.0 \pm 0.6$	$3.3 \pm 1.2$	0.686
Creatinine ( $\mu\text{mol/L}$ )	$83.9 \pm 11.9$	$86.4 \pm 19.4$	0.636
eGFR (2021 CKD-EPI Creatinine)	$84.5 \pm 13.7$	$79.6 \pm 17.4$	0.345

483 Table 6: The quality of the bicycle ergometry appeared quite low in our cohort.

Chars	Point estimate	95%CI
AUC	0.553	[0.406 0.695]
Sensitivity	0.263	[0.067 0.474]
Specificity	0.632	[0.409 0.833]
Negative predictive value	0.462	[0.269 0.654]
Positive predictive value	0.417	[0.143 0.714]

484 Table 7: The 20 most statically significant features according to the build model. Dltq\_01  
485 indicates the difference between the selected single channel ECG features immediately after  
486 the stress minus the selected features before the stress test.

	Feature	Lasso absolute coefficient
1.	<b>dltq_01_Pan...31</b>	0.589804
2.	<b>dltq_01_SA</b>	0.509832
3.	<b>dltq_01_JA</b>	0.37366
4.	<b>dltq_01_TE1</b>	0.270038
5.	<b>dltq_01_TpTe</b>	0.258854
6.	<b>dltq_01_HFNoise</b>	0.248446
7.	<b>dltq_01_PpeakN</b>	0.206324
8.	<b>dltq_01_QRS1energy</b>	0.190459
9.	<b>dltq_01_TA</b>	0.15963
10.	<b>dltq_01_Sbeta</b>	0.150864
11.	<b>dltq_01_TE3</b>	0.138504
12.	<b>dltq_01_Tenergy</b>	0.125174
13.	<b>dltq_01_TE4</b>	0.116375

14.	<b>dltq_01_Tpenergy</b>	0.106516
15.	<b>dltq_01_QTc</b>	0.102957
16.	<b>dltq_01_TE2</b>	0.102495
17.	<b>dltq_01_HFQRS</b>	0.090197
18.	<b>dltq_01_SDNN</b>	0.082806
19.	<b>dltq_01_QRSE1</b>	0.082143
20.	<b>dltq_01_QRSw</b>	0.063462

487

488 Table 8: The quality of the single channel ECG in the diagnosis of ischemic heart disease

489 using the Cardio-Qvark.

Chars	Point estimate	95%CI
AUC	0.684	[0.527 ; 0.817]
Sensitivity	0.737	[0.533 ; 0.929]
Specificity	0.632	[0.391 ; 0.833]
Negative predictive value	0.706	[0.47 ; 0.917]
Positive predictive value	0.667	[0.444 ; 0.857]

490